Analyst Reco. Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
3.9 ^USD	-5.80%		-4.41%	+4.28%

May. 10	Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating	MT
May. 10	Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating	May. 10	MT
Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating	May. 10	MT
Morgan Stanley Raises Fate Therapeutics Price Target to $7 From $3, Maintains Equalweight Rating	Feb. 27	MT
BMO Capital Adjusts Price Target on Fate Therapeutics to $7 From $6, Maintains Market Perform Rating	Feb. 27	MT
Barclays Adjusts Price Target on Fate Therapeutics to $10 From $6, Maintains Overweight Rating	Feb. 27	MT
Wedbush Raises Fate Therapeutics' Price Target to $7 From $3, Keeps Neutral Rating	Feb. 27	MT
Mizuho Lowers Price Target on Fate Therapeutics to $8 From $12, Maintains Buy Rating	Nov. 20	MT
Morgan Stanley Adjusts Price Target on Fate Therapeutics to $3 From $5, Maintains Equalweight Rating	Nov. 13	MT
Wells Fargo Trims Price Target on Fate Therapeutics to $5 From $6, Maintains Equalweight Rating	Nov. 09	MT
Wedbush Lowers Fate Therapeutics' Price Target to $3 From $6, Maintains Neutral Rating	Nov. 09	MT
Morgan Stanley Adjusts Price Target on Fate Therapeutics to $5 From $8, Keeps Equalweight Rating	23-08-10	MT
Barclays Adjusts Fate Therapeutics Price Target to $6 From $12, Maintains Overweight Rating	23-08-10	MT
BMO Capital Adjusts Price Target on Fate Therapeutics to $5.40 From $6, Maintains Market Perform Rating	23-08-09	MT
Wedbush Trims Fate Therapeutics' Price Target to $6 From $7, Keeps Neutral Rating	23-08-09	MT
Stifel Nicolaus Adjusts Fate Therapeutics Price Target to $5 From $5.30, Maintains Hold Rating	23-05-04	MT
Cantor Fitzgerald Adjusts Price Target on Fate Therapeutics to $5 From $8, Maintains Neutral Rating	23-05-04	MT
Wells Fargo Assumes Coverage on Fate Therapeutics With Equal Weight Rating, $6 Price Target	23-03-27	MT
Citigroup Adjusts Fate Therapeutics Price Target to $10 From $9, Maintains Buy Rating	23-03-02	MT
HC Wainwright Downgrades Fate Therapeutics to Neutral From Buy, Adjusts Price Target to $7 From $115	23-01-24	MT
Goldman Sachs Adjusts Price Target on Fate Therapeutics to $4 From $10, Maintains Sell Rating	23-01-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Analyst Reco.

Filters